Drug Trial Radar · NCT07454226
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
May 30, 2026
Primary completion
Mar 1, 2028
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, non-randomized, phase II exploratory study aims to evaluate the efficacy and safety of combining pathway-specific tyrosine kinase inhibitors with chemotherapy and venetoclax in patients with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL). Patients are stratified by genetic alteration: those with ABL class fusions (ABL1, ABL2, PDGFRA, PDGFRB) receive olverembatinib, while those with JAK pathway alterations (CRLF2 rearrangement, JAK mutation/fusion, EPOR fusion, SH2B3 deletion, IL7R mutation) receive Gecacitinib. Both groups undergo sequential induction, consolidation, intensification, and maintenance therapy as per protocol. The primary endpoint is the rate of flow cytometry minimal residual disease (MRD)-negative complete remission (CR MRD-) at 3 months after induction therapy. Secondary endpoints include overall complete remission rate, NGS MRD-negative CR rate at 3 months, overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), cumulative incidence of relapse, and 60-day mortality.
Conditions
- Ph-Like
- Acute Lymphoblastic Leukemia
Interventions
OlverembatinibDrug
Third-generation TKI targeting ABL class fusions. 40 mg every other day, continuous throughout all phases except during HD-MTX.
GecacitinibDrug
JAK1/2 inhibitor targeting JAK pathway alterations. 100 mg twice daily during CAMVT consolidation and maintenance.
VenetoclaxDrug
BCL-2 inhibitor. Escalating doses (100→200→400 mg) during induction; 400 mg during maintenance VP cycles.
Chemotherapy RegimenDrug
Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.
BlinatumomabDrug
Optional CD19-directed BiTE antibody. 28-day continuous infusions alternating with chemotherapy.
CAR-T Cell TherapyProcedure
Optional cellular immunotherapy preceded by fludarabine/cyclophosphamide lymphodepletion.
Allogeneic HSCTProcedure
Stem cell transplantation for eligible patients in first complete remission.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of flow cytometry-minimal residual disease (flow-MRD) negative complete remission at 3 months after treatment initiationTime frame: At 3 months after treatment initiation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Blood diseases hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.